caspofungin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antifungal antibiotics	2977	162808-62-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: caspofungin acetate caspofungin diacetate cancidas caspofungin MK-0991	Caspofungin, an echinocandin, inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of susceptible Aspergillus species and Candida species. Beta (1,3)-D-glucan is not present in mammalian cells. Caspofungin has shown activity against Candida species and in regions of active cell growth of the hyphae of Aspergillus fumigatus. Molecular weight: 1093.33 Formula: C52H88N10O15 CLOGP: -2.35 LIPINSKI: 3 HAC: 25 HDO: 16 TPSA: 412.03 ALOGS: -3.47 ROTB: 23 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

caspofungin acetate
caspofungin diacetate
cancidas
caspofungin
MK-0991

Caspofungin, an echinocandin, inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of susceptible Aspergillus species and Candida species. Beta (1,3)-D-glucan is not present in mammalian cells. Caspofungin has shown activity against Candida species and in regions of active cell growth of the hyphae of Aspergillus fumigatus.

Molecular weight: 1093.33
Formula: C52H88N10O15
CLOGP: -2.35
LIPINSKI: 3
HAC: 25
HDO: 16
TPSA: 412.03
ALOGS: -3.47
ROTB: 23

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
50	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1.40 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.91 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.13 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.14 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	27 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	15 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Jan. 26, 2001	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Systemic mycosis	256.85	27.97	53	8123	1144	63479702
Septic shock	230.11	27.97	129	8047	66500	63414346
Multiple organ dysfunction syndrome	226.72	27.97	121	8055	56631	63424215
Bronchopulmonary aspergillosis	176.63	27.97	59	8117	8576	63472270
Upper respiratory fungal infection	164.00	27.97	27	8149	151	63480695
Drug resistance	145.36	27.97	67	8109	22866	63457980
Drug ineffective	136.13	27.97	364	7812	1044401	62436445
Mucormycosis	129.27	27.97	36	8140	2835	63478011
Aspergillus infection	125.60	27.97	45	8131	8048	63472798
Diffuse large B-cell lymphoma refractory	122.30	27.97	29	8147	1201	63479645
Cholestasis	120.90	27.97	64	8112	29370	63451476
Systemic candida	120.47	27.97	35	8141	3210	63477636
Drug reaction with eosinophilia and systemic symptoms	115.25	27.97	65	8111	33771	63447075
Toxic epidermal necrolysis	112.37	27.97	58	8118	25276	63455570
Fusarium infection	100.82	27.97	22	8154	624	63480222
Febrile neutropenia	94.41	27.97	95	8081	118354	63362492
Venoocclusive liver disease	86.93	27.97	30	8146	4805	63476041
Pathogen resistance	85.99	27.97	32	8144	6366	63474480
Alternaria infection	83.32	27.97	16	8160	235	63480611
Cerebral aspergillosis	80.75	27.97	17	8159	405	63480441
Acute respiratory distress syndrome	79.54	27.97	45	8131	23489	63457357
Candida infection	76.86	27.97	47	8129	28304	63452542
Fatigue	73.73	27.97	13	8163	888015	62592831
Cytomegalovirus infection	73.35	27.97	41	8135	20911	63459935
Geotrichum infection	73.18	27.97	16	8160	458	63480388
Candida sepsis	69.97	27.97	19	8157	1361	63479485
Hepatocellular injury	68.17	27.97	43	8133	27338	63453508
Neutropenia	67.46	27.97	97	8079	174908	63305938
Disseminated intravascular coagulation	65.93	27.97	37	8139	19014	63461832
Fungal infection	65.60	27.97	47	8129	36827	63444019
Sepsis	65.14	27.97	89	8087	153034	63327812
Graft versus host disease	63.21	27.97	26	8150	6737	63474109
Toxic skin eruption	61.47	27.97	31	8145	12854	63467992
Fungaemia	59.56	27.97	19	8157	2384	63478462
Fungal sepsis	57.51	27.97	16	8160	1254	63479592
Product use in unapproved indication	54.52	27.97	89	8087	178991	63301855
Graft versus host disease in gastrointestinal tract	53.99	27.97	19	8157	3222	63477624
Adenoviral hepatitis	53.44	27.97	12	8164	389	63480457
Acute graft versus host disease	51.74	27.97	20	8156	4408	63476438
Respiratory failure	50.71	27.97	64	8112	101794	63379052
Thrombocytopenia	49.94	27.97	78	8098	151079	63329767
Capillary leak syndrome	48.84	27.97	16	8160	2184	63478662
Hepatic cytolysis	48.14	27.97	28	8148	15379	63465467
Hepatic failure	46.97	27.97	38	8138	35618	63445228
Enterococcal infection	46.81	27.97	22	8154	7826	63473020
Pyelonephritis fungal	46.44	27.97	9	8167	139	63480707
Acute kidney injury	44.50	27.97	102	8074	263313	63217533
Pain	44.49	27.97	20	8156	740608	62740238
Perinephric abscess	43.34	27.97	9	8167	200	63480646
Infective aneurysm	42.52	27.97	10	8166	399	63480447
Adenovirus infection	41.27	27.97	16	8160	3555	63477291
Dizziness	41.02	27.97	4	8172	429921	63050925
Emphysematous pyelonephritis	40.82	27.97	9	8167	268	63480578
Pancytopenia	40.66	27.97	56	8120	96877	63383969
Drug level decreased	40.56	27.97	20	8156	7899	63472947
Pseudomonas infection	39.39	27.97	22	8154	11191	63469655
Dilatation intrahepatic duct acquired	37.39	27.97	10	8166	676	63480170
Hepatic necrosis	37.21	27.97	17	8159	5670	63475176
Brain oedema	37.10	27.97	23	8153	14172	63466674
Eosinophilia	35.92	27.97	27	8149	22729	63458117
Staphylococcal scalded skin syndrome	35.22	27.97	7	8169	124	63480722
Trichosporon infection	34.92	27.97	8	8168	284	63480562
Venous haemorrhage	34.79	27.97	8	8168	289	63480557
Cerebral haemorrhage	34.77	27.97	30	8146	30699	63450147
Cytokine release syndrome	34.42	27.97	22	8154	14292	63466554
Liver abscess	33.73	27.97	13	8163	2841	63478005
Stevens-Johnson syndrome	33.72	27.97	27	8149	24923	63455923
Headache	33.67	27.97	20	8156	633221	62847625
Peritonitis	33.12	27.97	23	8153	17131	63463715
Abscess fungal	32.85	27.97	6	8170	66	63480780
Epidermolysis	32.80	27.97	9	8167	670	63480176
Haemophagocytic lymphohistiocytosis	32.37	27.97	19	8157	10608	63470238
Dyspnoea	32.29	27.97	23	8153	661290	62819556
Arthralgia	31.70	27.97	17	8159	569693	62911153
Drug level increased	31.57	27.97	25	8151	22711	63458135
Renal failure	31.16	27.97	55	8121	117597	63363249
Fungal endocarditis	30.91	27.97	7	8169	236	63480610
Nausea	30.90	27.97	39	8137	854432	62626414
Mucosal inflammation	30.82	27.97	34	8142	46894	63433952
Abdominal discomfort	30.55	27.97	3	8173	320882	63159964
Blood culture positive	30.49	27.97	14	8162	4721	63476125
Drug level below therapeutic	30.13	27.97	14	8162	4852	63475994
Graft versus host disease in skin	30	27.97	12	8164	2893	63477953
Hepatotoxicity	29.97	27.97	30	8146	37011	63443835
Fungal test positive	29.72	27.97	8	8168	554	63480292
Scedosporium infection	29.71	27.97	8	8168	555	63480291
Agranulocytosis	29.37	27.97	25	8151	25109	63455737
Drug hypersensitivity	29.32	27.97	3	8173	310684	63170162
Hyperbilirubinaemia	28.73	27.97	18	8158	11296	63469550
Pyrexia	28.61	27.97	128	8048	470350	63010496
Graft versus host disease in liver	28.48	27.97	8	8168	649	63480197
Shock haemorrhagic	28.33	27.97	17	8159	9878	63470968
Leukoencephalopathy	28.27	27.97	13	8163	4400	63476446

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	326.13	22.54	537	10345	456214	34489835
Multiple organ dysfunction syndrome	212.97	22.54	182	10700	76384	34869665
Aspergillus infection	208.20	22.54	93	10789	12161	34933888
Systemic mycosis	205.30	22.54	55	10827	1518	34944531
Drug resistance	201.79	22.54	116	10766	25811	34920238
Bronchopulmonary aspergillosis	153.94	22.54	80	10802	14579	34931470
Septic shock	139.80	22.54	140	10742	71694	34874355
Pathogen resistance	139.11	22.54	65	10817	9417	34936632
Dysplastic naevus	138.89	22.54	32	10850	464	34945585
Solar lentigo	135.65	22.54	32	10850	517	34945532
Photodermatosis	134.85	22.54	32	10850	531	34945518
Central nervous system fungal infection	121.98	22.54	27	10855	323	34945726
Candida infection	96.12	22.54	63	10819	17652	34928397
Fungaemia	83.24	22.54	31	10851	2537	34943512
Drug reaction with eosinophilia and systemic symptoms	78.62	22.54	72	10810	32940	34913109
Respiratory failure	75.32	22.54	127	10755	108445	34837604
Febrile neutropenia	74.46	22.54	144	10738	136705	34809344
Mucormycosis	72.77	22.54	36	10846	5906	34940143
Fungal infection	70.58	22.54	50	10832	15885	34930164
Actinic keratosis	69.11	22.54	32	10850	4535	34941514
Fusarium infection	68.79	22.54	22	10860	1138	34944911
Venoocclusive disease	65.98	22.54	27	10855	2840	34943209
Agranulocytosis	64.74	22.54	56	10826	23765	34922284
Sepsis	59.51	22.54	148	10734	166413	34779636
Systemic candida	59.17	22.54	27	10855	3699	34942350
Product use in unapproved indication	57.09	22.54	118	10764	117381	34828668
Fatigue	55.69	22.54	23	10859	370630	34575419
Nephrogenic diabetes insipidus	54.26	22.54	19	10863	1302	34944747
Cerebral aspergillosis	52.76	22.54	19	10863	1413	34944636
Differentiation syndrome	52.68	22.54	19	10863	1419	34944630
Cytomegalovirus infection	50.83	22.54	51	10831	26084	34919965
Enterococcal infection	50.22	22.54	33	10849	9273	34936776
Dizziness	50.16	22.54	5	10877	218516	34727533
Photosensitivity reaction	48.67	22.54	34	10848	10560	34935489
Hypokalaemia	48.38	22.54	74	10808	58140	34887909
Toxic epidermal necrolysis	45.36	22.54	44	10838	21602	34924447
Aortoenteric fistula	45.22	22.54	10	10872	119	34945930
Incision site pain	44.66	22.54	18	10864	1820	34944229
Cholestasis	44.19	22.54	48	10834	26900	34919149
Dyspnoea	44.06	22.54	32	10850	376750	34569299
Fall	43.19	22.54	6	10876	202879	34743170
Graft versus host disease in skin	42.84	22.54	22	10860	3903	34942146
Squamous cell carcinoma of skin	41.06	22.54	31	10851	10850	34935199
Geotrichum infection	40.21	22.54	12	10870	492	34945557
Lymphocyte count decreased	40.10	22.54	42	10840	22580	34923469
Endocarditis	39.86	22.54	25	10857	6486	34939563
Hyperleukocytosis	39.84	22.54	17	10865	1985	34944064
Trichosporon infection	39.77	22.54	13	10869	721	34945328
Graft versus host disease	39.63	22.54	30	10852	10539	34935510
Nausea	37.01	22.54	31	10851	339877	34606172
Pancytopenia	36.51	22.54	87	10795	95070	34850979
Splenic infection fungal	36.51	22.54	8	10874	91	34945958
Haemophagocytic lymphohistiocytosis	36.25	22.54	31	10851	12942	34933107
Organ failure	35.89	22.54	16	10866	2075	34943974
Weight decreased	35.71	22.54	6	10876	176295	34769754
Graft versus host disease in gastrointestinal tract	35.51	22.54	19	10863	3664	34942385
Pseudomonas infection	35.45	22.54	30	10852	12352	34933697
Electrocardiogram QT prolonged	35.34	22.54	53	10829	40899	34905150
Asthenia	33.97	22.54	17	10865	245234	34700815
Arthralgia	33.97	22.54	6	10876	170035	34776014
Encephalopathy	33.80	22.54	48	10834	35271	34910778
Lower respiratory tract infection fungal	33.71	22.54	11	10871	607	34945442
Bone marrow failure	32.91	22.54	43	10839	29210	34916839
Rectal perforation	32.19	22.54	10	10872	470	34945579
Acute respiratory distress syndrome	32.09	22.54	40	10842	25929	34920120
Mucosal inflammation	31.93	22.54	49	10833	38573	34907476
Pain	31.80	22.54	12	10870	204663	34741386
Red blood cells urine positive	31.56	22.54	14	10868	1795	34944254
Toxic skin eruption	31.39	22.54	27	10855	11358	34934691
Pulmonary mucormycosis	31.15	22.54	11	10871	772	34945277
Transaminases increased	31.06	22.54	40	10842	26783	34919266
Decreased appetite	30.88	22.54	7	10875	166385	34779664
Hepatic failure	30.24	22.54	45	10837	34486	34911563
Fungal endocarditis	30.11	22.54	9	10873	371	34945678
Systemic inflammatory response syndrome	29.58	22.54	21	10861	6688	34939361
Protein urine present	29.33	22.54	19	10863	5209	34940840
Vomiting	28.92	22.54	21	10861	247600	34698449
Hyperbilirubinaemia	27.60	22.54	30	10852	16813	34929236
Haemodynamic instability	27.11	22.54	23	10859	9500	34936549
Spinal cord disorder	26.47	22.54	10	10872	851	34945198
Cytokine release syndrome	26.31	22.54	34	10848	22843	34923206
Hypogonadism	25.65	22.54	13	10869	2242	34943807
Malaise	25.53	22.54	13	10869	185812	34760237
Scopulariopsis infection	25.09	22.54	6	10876	103	34945946
Chimerism	24.77	22.54	7	10875	236	34945813
Off label use	24.65	22.54	218	10664	419306	34526743
Venoocclusive liver disease	24.25	22.54	20	10862	7946	34938103
Procedural pain	23.42	22.54	16	10866	4790	34941259
Hypoperfusion	23.39	22.54	10	10872	1173	34944876
Hepatotoxicity	23.26	22.54	31	10851	21454	34924595
Klebsiella infection	23.05	22.54	20	10862	8511	34937538

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	495.60	22.72	877	17257	1080036	78646218
Systemic mycosis	447.46	22.72	107	18027	2559	79723695
Multiple organ dysfunction syndrome	384.18	22.72	273	17861	119973	79606281
Bronchopulmonary aspergillosis	336.81	22.72	142	17992	22152	79704102
Aspergillus infection	316.23	22.72	130	18004	19031	79707223
Septic shock	301.12	22.72	238	17896	122563	79603691
Pathogen resistance	205.44	22.72	88	18046	14254	79712000
Drug resistance	195.57	22.72	121	18013	42092	79684162
Mucormycosis	169.30	22.72	66	18068	8403	79717851
Drug reaction with eosinophilia and systemic symptoms	169.14	22.72	130	18004	64114	79662140
Systemic candida	165.65	22.72	61	18073	6645	79719609
Candida infection	163.09	22.72	104	18030	38110	79688144
Febrile neutropenia	157.13	22.72	226	17908	230773	79495481
Upper respiratory fungal infection	153.58	22.72	31	18103	324	79725930
Dysplastic naevus	143.07	22.72	32	18102	563	79725691
Toxic epidermal necrolysis	141.55	22.72	101	18033	44480	79681774
Cholestasis	129.65	22.72	102	18032	52007	79674247
Fusarium infection	129.46	22.72	37	18097	1795	79724459
Photodermatosis	127.72	22.72	32	18102	932	79725322
Respiratory failure	125.87	22.72	179	17955	180732	79545522
Fatigue	125.74	22.72	29	18105	929698	78796556
Solar lentigo	122.59	22.72	32	18102	1101	79725153
Central nervous system fungal infection	117.53	22.72	26	18108	434	79725820
Fungaemia	114.26	22.72	42	18092	4549	79721705
Cytomegalovirus infection	113.75	22.72	87	18047	42557	79683697
Graft versus host disease	112.58	22.72	59	18075	14967	79711287
Geotrichum infection	107.55	22.72	28	18106	953	79725301
Sepsis	104.43	22.72	205	17929	269223	79457031
Fungal infection	95.90	22.72	78	18056	41670	79684584
Product use in unapproved indication	93.99	22.72	188	17946	250171	79476083
Venoocclusive liver disease	93.29	22.72	48	18086	11723	79714531
Acute respiratory distress syndrome	92.21	22.72	78	18056	43989	79682265
Enterococcal infection	88.37	22.72	51	18083	15609	79710645
Dizziness	87.76	22.72	9	18125	526432	79199822
Venoocclusive disease	85.64	22.72	34	18100	4539	79721715
Agranulocytosis	84.70	22.72	75	18059	44955	79681299
Cerebral aspergillosis	82.42	22.72	26	18108	1770	79724484
Pancytopenia	80.38	22.72	139	17995	165606	79560648
Pain	78.62	22.72	31	18103	703771	79022483
Dyspnoea	77.45	22.72	50	18084	856975	78869279
Toxic skin eruption	76.53	22.72	53	18081	22240	79704014
Nausea	71.18	22.72	68	18066	957128	78769126
Haemophagocytic lymphohistiocytosis	70.49	22.72	50	18084	21787	79704467
Actinic keratosis	70.14	22.72	32	18102	6010	79720244
Trichosporon infection	69.62	22.72	20	18114	988	79725266
Arthralgia	69.27	22.72	22	18112	571781	79154473
Fall	68.18	22.72	14	18120	487615	79238639
Hepatocellular injury	67.89	22.72	68	18066	47525	79678729
Pseudomonas infection	67.80	22.72	48	18086	20855	79705399
Hepatic failure	67.03	22.72	76	18058	61136	79665118
Headache	66.37	22.72	33	18101	653739	79072515
Candida sepsis	62.57	22.72	23	18111	2490	79723764
Bone marrow failure	60.33	22.72	66	18068	51041	79675213
Cytokine release syndrome	59.93	22.72	56	18078	35942	79690312
Differentiation syndrome	58.80	22.72	22	18112	2502	79723752
Alternaria infection	58.34	22.72	16	18118	666	79725588
Acute graft versus host disease	57.07	22.72	33	18101	10134	79716120
Incision site pain	56.36	22.72	22	18112	2808	79723446
Systemic inflammatory response syndrome	55.95	22.72	34	18100	11431	79714823
Electrocardiogram QT prolonged	54.92	22.72	84	18050	90302	79635952
Nephrogenic diabetes insipidus	54.87	22.72	20	18114	2114	79724140
Encephalopathy	54.81	22.72	72	18062	67325	79658929
Disseminated intravascular coagulation	54.43	22.72	53	18081	35789	79690465
Organ failure	52.04	22.72	23	18111	4010	79722244
Vomiting	50.92	22.72	46	18088	665782	79060472
Graft versus host disease in gastrointestinal tract	50.60	22.72	26	18108	6330	79719924
Hyperbilirubinaemia	50.46	22.72	43	18091	24475	79701779
Weight decreased	50.02	22.72	10	18124	355188	79371066
Mucosal inflammation	49.85	22.72	73	18061	75507	79650747
Eosinophilia	49.13	22.72	56	18078	45289	79680965
Adenovirus infection	48.96	22.72	28	18106	8419	79717835
Malaise	47.77	22.72	26	18108	489843	79236411
Red blood cells urine positive	47.48	22.72	23	18111	4940	79721314
Aortoenteric fistula	46.65	22.72	10	18124	143	79726111
Transaminases increased	46.35	22.72	58	18076	51685	79674569
Staphylococcal scalded skin syndrome	46.30	22.72	12	18122	401	79725853
Graft versus host disease in skin	45.92	22.72	24	18110	6049	79720205
Asthenia	45.90	22.72	30	18104	511659	79214595
Hypokalaemia	45.62	22.72	101	18033	143939	79582315
Abdominal discomfort	45.26	22.72	3	18131	250724	79475530
Hepatotoxicity	45.10	22.72	57	18077	51295	79674959
Hepatic function abnormal	43.08	22.72	67	18067	73040	79653214
Abscess fungal	42.99	22.72	11	18123	349	79725905
Fungal sepsis	42.81	22.72	16	18118	1814	79724440
Squamous cell carcinoma of skin	42.69	22.72	31	18103	14002	79712252
Renal failure	42.67	22.72	121	18013	200847	79525407
Drug interaction	42.60	22.72	197	17937	414986	79311268
Lymphocyte count decreased	42.34	22.72	53	18081	47236	79679018
Scedosporium infection	42.32	22.72	15	18119	1463	79724791
Klebsiella infection	41.74	22.72	32	18102	15688	79710566
Lower respiratory tract infection fungal	41.35	22.72	13	18121	875	79725379
Photosensitivity reaction	41.34	22.72	36	18098	21091	79705163
Rash maculo-papular	41.16	22.72	57	18077	56021	79670233
Alopecia	41.09	22.72	3	18131	231352	79494902
Drug hypersensitivity	40.87	22.72	9	18125	298907	79427347
Endocarditis	40.67	22.72	27	18107	10570	79715684
Hyperleukocytosis	40.63	22.72	17	18117	2593	79723661
Chimerism	40.08	22.72	10	18124	286	79725968
Infective aneurysm	39.73	22.72	13	18121	995	79725259
Fungal test positive	38.66	22.72	13	18121	1083	79725171
Acute kidney injury	38.43	22.72	225	17909	519179	79207075
Swelling	37.94	22.72	3	18131	216708	79509546
Drug level below therapeutic	37.75	22.72	25	18109	9745	79716509
Splenic infection fungal	37.68	22.72	8	18126	109	79726145
Drug level decreased	37.54	22.72	29	18105	14373	79711881
Off label use	37.18	22.72	341	17793	906874	78819380
Pyelonephritis fungal	37.04	22.72	9	18125	230	79726024
Protein urine present	36.97	22.72	25	18109	10087	79716167
Stevens-Johnson syndrome	36.84	22.72	45	18089	39121	79687133
Adenoviral hepatitis	36.72	22.72	12	18122	915	79725339
Decreased appetite	36.65	22.72	16	18118	342402	79383852
Weight increased	36.64	22.72	9	18125	277377	79448877
Hepatitis fulminant	36.63	22.72	22	18112	7240	79719014
Perinephric abscess	36.19	22.72	9	18125	254	79726000
Drug intolerance	36.01	22.72	8	18126	264111	79462143
Neutropenia	35.20	22.72	144	17990	287566	79438688
Pruritus	34.21	22.72	24	18110	394624	79331630
Cerebral haemorrhage	34.18	22.72	53	18081	57620	79668634
Pulmonary mucormycosis	34.03	22.72	12	18122	1153	79725101
Emphysematous pyelonephritis	33.61	22.72	9	18125	342	79725912
Infusion related reaction	33.42	22.72	6	18128	230231	79496023
Gait disturbance	33.37	22.72	4	18130	207502	79518752
Fungal endocarditis	32.86	22.72	10	18124	604	79725650
BK virus infection	32.74	22.72	22	18112	8782	79717472
Pain in extremity	31.82	22.72	22	18112	364516	79361738
Blood pressure increased	31.80	22.72	5	18129	211355	79514899
Leukopenia	31.71	22.72	77	18057	116436	79609818
Drug ineffective for unapproved indication	31.64	22.72	48	18086	51190	79675064
Neutrophil count increased	31.32	22.72	36	18098	29360	79696894
Shock haemorrhagic	31.09	22.72	30	18104	20030	79706224
Dilatation intrahepatic duct acquired	31.05	22.72	10	18124	728	79725526
Anxiety	31.04	22.72	9	18125	248503	79477751
Disseminated mucormycosis	30.91	22.72	10	18124	738	79725516
Depression	30.71	22.72	6	18128	216784	79509470
Insomnia	30.40	22.72	9	18125	245161	79481093
Pneumonia fungal	30.15	22.72	23	18111	11187	79715067
Drug level increased	30.14	22.72	41	18093	39610	79686644
Rectal perforation	29.04	22.72	10	18124	895	79725359
Venous haemorrhage	28.87	22.72	8	18126	346	79725908
Haemodynamic instability	28.85	22.72	27	18107	17355	79708899
Bacteraemia	28.13	22.72	36	18098	32788	79693466
Renal abscess	27.20	22.72	10	18124	1083	79725171
Therapeutic product effect decreased	26.74	22.72	3	18131	163860	79562394
Pulmonary haemorrhage	26.64	22.72	24	18110	14693	79711561
Sinusitis	26.48	22.72	6	18128	195495	79530759
Abdominal pain upper	26.35	22.72	9	18125	223810	79502444
Scopulariopsis infection	26.05	22.72	6	18128	121	79726133
Dehydration	25.91	22.72	12	18122	248175	79478079
Back pain	25.69	22.72	19	18115	304161	79422093
Immunosuppressant drug level increased	25.34	22.72	19	18115	9008	79717246
Hepatic cytolysis	25.21	22.72	31	18103	27120	79699134
Hepatic necrosis	25.20	22.72	19	18115	9081	79717173
Acute graft versus host disease in intestine	25.05	22.72	14	18120	4027	79722227
Disseminated trichosporonosis	24.75	22.72	6	18128	152	79726102
Fungal skin infection	24.67	22.72	16	18118	6020	79720234
Epidermolysis	24.62	22.72	9	18125	959	79725295
Thrombocytopenia	24.36	22.72	122	18012	265137	79461117
Hyperhidrosis	24.15	22.72	3	18131	151489	79574765
Blood bilirubin increased	23.90	22.72	49	18085	66183	79660071
Acute myeloid leukaemia	23.57	22.72	32	18102	30853	79695401
Nephropathy toxic	23.45	22.72	26	18108	20393	79705861
Bacterial infection	23.25	22.72	32	18102	31248	79695006
White blood cell count increased	23.23	22.72	52	18082	74581	79651673
Staphylococcal sepsis	22.77	22.72	22	18112	14704	79711550

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J02AX04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Other antimycotics for systemic use
FDA CS	M0519359	Lipopeptides
FDA EPC	N0000175507	Echinocandin Antifungal
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D004791	Enzyme Inhibitors
CHEBI has role	CHEBI:35441	antiinfective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Candidiasis of the esophagus	indication	20639004	DOID:13146
Candidemia	indication	432261003
Intra-Abdominal Candida Abscess	indication
Candida Pleural Space Infection	indication
Refractory Aspergillosis	indication
Candida Peritonitis	indication
Oropharyngeal Candidiasis	off-label use
Hypokalemia	contraindication	43339004
Liver function tests abnormal	contraindication	166603001
Disease of liver	contraindication	235856003	DOID:409

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.55	acidic
pKa2	11.98	acidic
pKa3	13.1	acidic
pKa4	13.77	acidic
pKa5	13.84	acidic
pKa6	10.04	Basic
pKa7	9.05	Basic
pKa8	4.09	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.22	CHEMBL
Beta-1,3-glucan synthase catalytic subunit 1	Enzyme		O13428_CANAX	INHIBITOR	IC50	8.89	WOMBAT-PK	CHEMBL
1,3-beta-glucan synthase catalytic subunit FksP	Enzyme		Q4WLT4_ASPFU	INHIBITOR			CHEMBL	CHEMBL
1,3-beta-D-glucan synthase catalytic subunit	Unclassified		O13383_CANAX		IC50	9.62	CHEMBL

External reference:

ID	Source
4021254	VUID
N0000148695	NUI
D02501	KEGG_DRUG
179463-17-3	SECONDARY_CAS_RN
4021253	VANDF
4021254	VANDF
C0537894	UMLSCUI
CHEBI:474180	CHEBI
CHEMBL499808	ChEMBL_ID
CHEMBL4297142	ChEMBL_ID
D000077336	MESH_DESCRIPTOR_UI
DB00520	DRUGBANK_ID
7778	INN_ID
F0XDI6ZL63	UNII
16119814	PUBCHEM_CID
140108	RXNORM
15896	MMSL
260563	MMSL
41099	MMSL
d04748	MMSL
009069	NDDF
009070	NDDF
129474002	SNOMEDCT_US
407732005	SNOMEDCT_US
413770001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CANCIDAS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3822	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	NDA	28 sections
CANCIDAS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3822	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	NDA	28 sections
CANCIDAS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3823	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	NDA	28 sections
CANCIDAS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3823	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	NDA	28 sections
CASPOFUNGIN ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3421	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	27 sections
CASPOFUNGIN ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3423	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	ANDA	27 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-194	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	31 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-195	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	ANDA	31 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	63323-356	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	NDA	29 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	63323-358	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	NDA	29 sections
Caspofungin Acetate	Human Prescription Drug Label	1	68083-158	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	26 sections
Caspofungin Acetate	Human Prescription Drug Label	1	68083-159	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	ANDA	26 sections
caspofungin acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-365	INJECTION	5 mg	INTRAVENOUS	ANDA	23 sections
caspofungin acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-366	INJECTION	7 mg	INTRAVENOUS	ANDA	23 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	70860-106	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	28 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	70860-106	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	28 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	70860-107	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	70 mg	INTRAVENOUS	ANDA	28 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	70860-107	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	70 mg	INTRAVENOUS	ANDA	28 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	72266-106	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	26 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	72266-106	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	26 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	72266-107	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	ANDA	26 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	72266-107	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	ANDA	26 sections
caspofungin acetate	HUMAN PRESCRIPTION DRUG LABEL	1	72611-700	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	28 sections
caspofungin acetate	HUMAN PRESCRIPTION DRUG LABEL	1	72611-700	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	28 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	72611-702	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	ANDA	28 sections
Caspofungin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	72611-702	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	ANDA	28 sections
CASPOFUNGIN ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	72843-434	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 mg	INTRAVENOUS	ANDA	28 sections
CASPOFUNGIN ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	72843-533	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	7 mg	INTRAVENOUS	ANDA	28 sections